Skip to main content
SpringerLink
Log in

Trattamento sequenziale con everolimus e sunitinib in tumori neuroendocrini pancreatici, ben differenziati, metastatici, resistenti alle precedenti terapie

  • Novità in Endocrinologia
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Pavel ME, Hainsworth JD, Baudin E et al. (for the RADIANT-2 Study Group) (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012

    Article  CAS  PubMed  Google Scholar 

  2. Yao JC, Fazio N, Singh S et al. (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–977

    Article  CAS  PubMed  Google Scholar 

  3. Raymond E, Hammel P, Dreyer C et al. (2012) Sunitinib in pancreatic neuroendocrine tumors. Target Oncol 7(2):117–125

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Endocrinologia, Dipartimento di Medicina Clinica e Chirurgia, Università Federico II di Napoli, Napoli, Italia

    Silvana Di Maio & Antongiulio Faggiano

Authors
  1. Silvana Di Maio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antongiulio Faggiano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antongiulio Faggiano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Maio, S., Faggiano, A. Trattamento sequenziale con everolimus e sunitinib in tumori neuroendocrini pancreatici, ben differenziati, metastatici, resistenti alle precedenti terapie. L'Endocrinologo 19, 333–334 (2018). https://doi.org/10.1007/s40619-018-00504-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-018-00504-x

Search

Navigation